Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
[HTML][HTML] A retrospective comparison of the clinical efficacy of gefitinib, erlotinib, and afatinib in Japanese patients with non-small cell lung cancer
A Fujiwara, M Yoshida, H Fujimoto, H Nakahara… - Oncology …, 2018 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR …
HA Jung, S Park, JM Sun, SH Lee, JS Ahn, MJ Ahn… - Biology, 2020 - mdpi.com
Simple Summary The present study showed the comprehensive analysis of disease
characteristics and treatment patterns in uncommon EGFR mutation-positive NSCLC at a …
characteristics and treatment patterns in uncommon EGFR mutation-positive NSCLC at a …
[HTML][HTML] Impact of smoking status on EGFR-TKI efficacy for advanced non–small-cell lung cancer in EGFR mutants: a meta-analysis
Background The strong association between smoking history and the presence of epidermal
growth factor receptor (EGFR) mutations has been proven in non–small-cell lung cancer …
growth factor receptor (EGFR) mutations has been proven in non–small-cell lung cancer …
Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase …
SH Hsiao, HE Liu, HL Lee, CL Lin, WY Chen, ZH Wu… - PLoS …, 2013 - journals.plos.org
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR …
E Nadler, M Pavilack, JL Espirito, J Clark… - Advances in …, 2020 - Springer
Introduction Epidermal growth factor receptor (EGFR) mutations are observed in
approximately 15% of patients with non-small cell lung cancer (NSCLC) in the USA. Little is …
approximately 15% of patients with non-small cell lung cancer (NSCLC) in the USA. Little is …
Post-progression survival after EGFR-TKI for advanced non-small cell lung cancer harboring EGFR mutations
Background Non-small cell lung cancer (NSCLC) patients that harbor epidermal growth
factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor …
factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor …
The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
X Yu, J Si, J Wei, Y Wang, Y Sun, J Jin… - Cancer …, 2023 - Wiley Online Library
Background Few large‐scale studies have been published using real‐world data related to
overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR) …
overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR) …
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
CK Lee, L Davies, YL Wu, T Mitsudomi… - JNCI: Journal of the …, 2017 - academic.oup.com
Background: We performed an individual patient data meta-analysis to examine the impact
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer …
A Rossi, R Pasquale, C Esposito… - Cancer Treatment Reviews, 2013 - Elsevier
An ideal target-based agent for the treatment of cancer patients should fulfil a number of
requirements, including the availability of biomarkers to select the target population …
requirements, including the availability of biomarkers to select the target population …